CAR-redirected natural killer T cells demonstrate superior antitumor activity to CAR-T cells through multimodal CD1d-dependent mechanisms
Compared to CAR.CD19 T cells, we found that CAR.CD19 NKTs showed superior control of tumor growth in the B16-OVA-hCD19 melanoma model without evident toxicity. To investigate whetehr   CAR.CD19 NKTs could affect the TME in the tumor. We used the single RNA seq to test the TME cell populations in the B16-OVA-hCD19 model between CAR.CD19 NKTs and CAR.CD19 Ts. Overall design: 8-10 weeks male mice injected the  B16-OVA-hCD19 tumors and received non-transduced T cells, CAR.CD19 T cells or CAR.CD19 NKTs and 16 days later isolate the cells infiltrated the tumors. 5 mice each group.